Literature DB >> 34036365

Especially for neuro-oncologists-minimally important differences for the EORTC QLQ-C30 in glioma patients.

Tito R Mendoza1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34036365      PMCID： PMC8328004          DOI： 10.1093/neuonc/noab124

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  6 in total

Review 1.  A point of minimal important difference (MID): a critique of terminology and methods.

Authors:  Madeleine T King
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2011-04       Impact factor: 2.217

2.  Patient-reported outcomes: an essential component of oncology drug development and regulatory review.

Authors:  Ethan Basch
Journal:  Lancet Oncol       Date:  2018-05       Impact factor: 41.316

3.  Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.

Authors:  Jammbe Z Musoro; Andrew Bottomley; Corneel Coens; Alexander Mm Eggermont; Madeleine T King; Kim Cocks; Mirjam Ag Sprangers; Mogens Groenvold; Galina Velikova; Hans-Henning Flechtner; Yvonne Brandberg
Journal:  Eur J Cancer       Date:  2018-10-22       Impact factor: 9.162

4.  Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop.

Authors:  Paul G Kluetz; Bindu Kanapuru; Steven Lemery; Laura Lee Johnson; Mallorie H Fiero; Karen Arscott; Yolanda Barbachano; Ethan Basch; Michelle Campbell; Joseph C Cappelleri; David Cella; Charles Cleeland; Corneel Coens; Selena Daniels; Crystal S Denlinger; Dianne L Fairclough; James R Hillard; Lori Minasian; Sandra A Mitchell; Daniel O'Connor; Sheetal Patel; Eric H Rubin; Anna Ryden; Katherine Soltys; Rajeshwari Sridhara; Gita Thanarajasingam; Galina Velikova; Stephen Joel Coons
Journal:  Value Health       Date:  2017-11-07       Impact factor: 5.725

5.  Minimally Important Differences for Interpreting EORTC QLQ-C30 Scores in Patients With Advanced Breast Cancer.

Authors:  Jammbe Z Musoro; Corneel Coens; Frederic Fiteni; Pogoda Katarzyna; Fatima Cardoso; Nicola S Russell; Madeleine T King; Kim Cocks; Mirjam Ag Sprangers; Mogens Groenvold; Galina Velikova; Hans-Henning Flechtner; Andrew Bottomley
Journal:  JNCI Cancer Spectr       Date:  2019-06-04

6.  Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.

Authors:  Linda Dirven; Jammbe Z Musoro; Corneel Coens; Jaap C Reijneveld; Martin J B Taphoorn; Florien W Boele; Mogens Groenvold; Martin J van den Bent; Roger Stupp; Galina Velikova; Kim Cocks; Mirjam A G Sprangers; Madeleine T King; Hans-Henning Flechtner; Andrew Bottomley
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.